Explore the latest advances in biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD). Stay informed about these key tools for diagnosis and management.
Disease awareness, patient stratification, diagnosis, and access to care are all helped or hindered by a pathology’s nomenclature. Indeed, the language used to name and identify a disease has the power to create or intensify social stigma, marginalise subsets of a patient population, and perpetuate health inequalities.
Models of care (MoCs) establish comprehensive frameworks for the provision of healthcare services along a continuum of care.
Interventional trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, are often limited by patient heterogeneity and, hence, response variability.